Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- XBRANE.ST
- Price
- 0.20
- Stock movement up
- +0.01 (8.00%)
- Company name
- Xbrane Biopharma AB
- Exchange
- (ST ,
- Currency
- SEK )
- Sector
- Healthcare >Biotechnology
- Market cap
- 301.31M
- Ent value
- 850.24M
- Price/Sales
- 1.51
- Price/Book
- 1.16
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- 4.71
- PEG
- -
- EPS growth
- -5.36%
- 1 year return
- -48.36%
- 3 year return
- -87.44%
- 5 year return
- -64.16%
- 10 year return
- -
Last updated: 2025-04-12
DIVIDENDS
XBRANE.ST does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 1.51 |
| Price to Book | 1.16 |
| EV to Sales | 4.26 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 1.53B |
| EPS (TTM) | -0.24 |
| FCF per share (TTM) | -0.22 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 199.77M |
| Gross profit (TTM) | 114.49M |
| Operating income (TTM) | -273.61M |
| Net income (TTM) | -370.56M |
| EPS (TTM) | -0.24 |
| EPS (1y forward) | 0.04 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 57.31% |
| Operating margin (TTM) | -136.96% |
| Profit margin (TTM) | -185.49% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 30.59M |
| Net receivables | 140.82M |
| Total current assets | 639.03M |
| Goodwill | 0.00 |
| Intangible assets | 125.96M |
| Property, plant and equipment | 0.00 |
| Total assets | 839.67M |
| Accounts payable | 194.72M |
| Short/Current long term debt | 170.36M |
| Total current liabilities | 474.16M |
| Total liabilities | 579.52M |
| Shareholder's equity | 260.15M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -308.77M |
| Capital expenditures (TTM) | 35.12M |
| Free cash flow (TTM) | -343.89M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -142.44% |
| Return on Assets | -44.13% |
| Return on Invested Capital | -113.97% |
| Cash Return on Invested Capital | -105.76% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 0.18 |
| Daily high | 0.21 |
| Daily low | 0.17 |
| Daily Volume | 8.59M |
| All-time high | 176.00 |
| 1y analyst estimate | 0.45 |
| Beta | 0.99 |
| EPS (TTM) | -0.24 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 8 May 2025 |
Downside potential
Loading...
Downside potential data
| XBRANE.ST | S&P500 | |
| Current price drop from All-time high | -99.89% | -12.89% |
| Highest price drop | -99.93% | -56.47% |
| Date of highest drop | 11 Sep 2024 | 9 Mar 2009 |
| Avg drop from high | -47.39% | -11.07% |
| Avg time to new high | 58 days | 12 days |
| Max time to new high | 968 days | 1805 days |
COMPANY DETAILS
Marketcap
301.31M
Marketcap category
Small-cap
Description
Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of wet age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults. Its pre-clinical phase products include BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis, Crohn's disease, and axial spondylitis; Xdivane, a nivolumab biosimilar candidate, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; and Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma. The company was incorporated in 2008 and is headquartered in Solna, Sweden.
Employees
65
Website
Investor relations
-
SEC filings
CEO
Country
Sweden
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
No items found